Share Price | Asston Pharmaceuticals Ltd Stock Analysis & Recommendation

Q: How has been the historical performance of Asston Pharmaceu?

Answer:The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.Breakdown:Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28.10 Cr from 20.70 Cr. The book value per share adjusted increased to 17.6 from 11.45, reflecting the company's strengthening financial position.

Q: Is Asston Pharmaceu overvalued or undervalued?

As of 26 November 2025, Asston Pharmaceu's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.In comparison to its peers, Asston Pharmaceu's PE ratio is lower than that of Sun Pharma (37.53) and Divi's Lab (69.71), both categorized as expensive, while it is slightly higher than Cipla (22.59) and Dr. Reddy's Labs (18.02), which are viewed as attractive. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 17.65% compared to the Sensex's 0.50%, reinforcing the notion of overvaluation in the current market context.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.0 k (150.00%) Volume

Shareholding (Mar 2026)

FII

1.91%

Held by 1 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

50.66%

How has been the historical performance of Asston Pharmaceu?

15-Nov-2025

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

View full answer

Is Asston Pharmaceu overvalued or undervalued?

27-Nov-2025

As of November 26, 2025, Asston Pharmaceu is considered overvalued with a PE ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35, despite outperforming the Sensex with a 1-week return of 17.65%.

View full answer

When is the next results date for Asston Pharmaceuticals Ltd?

22-May-2026

The next results date for Asston Pharmaceuticals Ltd is 29 May 2026.

View full answer

Why is Asston Pharmaceuticals Ltd falling/rising?

03-Jun-2026

As of 02-Jun, the stock price of Asston Pharmaceuticals Ltd is at 73.01, showing short-term gains but trading below all key moving averages, indicating a longer-term downward trend and reduced investor participation.

View full answer

Which are the latest news on Asston Pharmaceu?

03-Jun-2026

When is the next results date for Asston Pharmaceuticals Ltd?

Compare Asston Pharmaceu with Similar Stocks

Samrat Pharma Biofil Chemicals Sunil Healthcare

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 60 Cr (Micro Cap)

P/E

16.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.10

Return on Equity

9.97%

Price to Book

1.54

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-8.74%

6 Months

-26.25%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Asston Pharmaceu for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

When is the next results date for Asston Pharmaceuticals Ltd?

The next results date for Asston Pharmaceuticals Ltd is scheduled for 29 May 2026....

Read full news article

Announcements

Audited Financial Results For The Financial Year Ended 31St March 2026.

29-May-2026 | Source : BSE

Audited Financial Results for the Financial Year ended 31st March 2026

Audited Financial Results For The Financial Year Ended 31St March 2026.

29-May-2026 | Source : BSE

Audited Financial Results for the Financial Year ended 31st March 2026

Board Meeting Outcome for Outcome Of The Board Meeting Held On 29Th May 2026

29-May-2026 | Source : BSE

Outcome of Board Meeting scheduled to be held on 29th May 2026

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

60.60%

EBIT Growth (5y)

143.20%

EBIT to Interest (avg)

2.34

Debt to EBITDA (avg)

0.73

Net Debt to Equity (avg)

0.64

Sales to Capital Employed (avg)

0.59

Tax Ratio

15.90%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

1.91%

ROCE (avg)

12.72%

ROE (avg)

29.08%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.61

EV to EBIT

-65.96

EV to EBITDA

-65.96

EV to Capital Employed

1.55

EV to Sales

2.59

PEG Ratio

Dividend Yield

ROCE (Latest)

-2.10%

ROE (Latest)

10.02%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 1 FIIs (1.91%)

Promoter with highest holding

Ashish Narayan Sakalkar (21.77%)

Highest Public shareholder

Mahesh Vishnupant Mulay (2.91%)

Individual Investors Holdings

40.53%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Asston Pharmaceu"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 70.01% vs -43.21% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -98.46% vs 2.63% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.42",
          "val2": "9.07",
          "chgp": "70.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.24",
          "val2": "3.17",
          "chgp": "-29.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.28",
          "val2": "0.53",
          "chgp": "-47.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.35",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.03",
          "val2": "1.95",
          "chgp": "-98.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.53%",
          "val2": "34.95%",
          "chgp": "-20.42%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Asston Pharmaceu"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.04",
          "val2": "15.59",
          "chgp": "60.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.44",
          "val2": "2.55",
          "chgp": "113.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.95",
          "val2": "0.93",
          "chgp": "2.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "3.85",
          "val2": "1.36",
          "chgp": "183.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.73%",
          "val2": "16.36%",
          "chgp": "5.37%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Mar'25

Change(%)

Net Sales

15.42

9.07

70.01%

Operating Profit (PBDIT) excl Other Income

2.24

3.17

-29.34%

Interest

0.28

0.53

-47.17%

Exceptional Items

-3.35

0.00

Standalone Net Profit

0.03

1.95

-98.46%

Operating Profit Margin (Excl OI)

14.53%

34.95%

-20.42%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2025 is 70.01% vs -43.21% in Mar 2025

Standalone Net Profit

Growth in half year ended Sep 2025 is -98.46% vs 2.63% in Mar 2025

All Half Yearly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

25.04

15.59

60.62%

Operating Profit (PBDIT) excl Other Income

5.44

2.55

113.33%

Interest

0.95

0.93

2.15%

Exceptional Items

0.00

Standalone Net Profit

3.85

1.36

183.09%

Operating Profit Margin (Excl OI)

21.73%

16.36%

5.37%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd

Micro Cap

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available